Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Avanir Pharmaceuticals Inc. Stories

2014-03-26 08:30:13

ALISO VIEJO, Calif., March 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO As previously reported the company's 505(b)(2) NDA for AVP-825 includes data from...

2014-03-20 08:30:39

Data shows that dextromethorphan exerts antidepressant-like actions mediated at least in part through sigma-1 receptors ALISO VIEJO, Calif., March 20, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the...

2014-03-19 16:23:40

ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a...

2014-03-19 08:30:22

Majority of Responding Veterans Surveyed Report Having PBA Symptoms, Adding an Extra Burden to Managing Life Post-TBI ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury (TBI) conducted in collaboration with the Department of Veterans Affairs (VA) and Evidera. The study will be presented at the...

2014-02-28 08:25:59

ALISO VIEJO, Calif., Feb. 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO -- Cowen & Company 34(th) Annual Healthcare Conference -- Location: Boston Marriott Copley Place, Boston, MA -- Presentation date: Tuesday March 4, 2014 -- Presentation time: 10:40 a.m....

2014-02-07 16:24:36

ALISO VIEJO, Calif., Feb. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on February 4, 2014, the Company approved the grant of stock options to new employees to purchase a total of 48,400 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4). (Logo:...

2014-02-05 16:27:36

ALISO VIEJO, Calif., Feb. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights -- Total company net revenues of $26.7 million -- Gross and net NUEDEXTA® sales increased to $31.3 million and $23.3 million, respectively -- Cash, cash equivalents, and restricted investments of $46.5...

2014-01-30 08:32:03

ALISO VIEJO, Calif., Jan. 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its innovative Breath Powered(TM) investigational drug-device combination product for the acute treatment of migraine. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) The company's 505(b)(2) NDA for AVP-825 includes data from one...

2014-01-13 08:27:28

ALISO VIEJO, Calif., Jan. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the quarter-ended December 31, 2013, in anticipation of the company's attendance at the J.P. Morgan 32(nd) Annual Healthcare Conference. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Based on preliminary financial information (unaudited) for the quarter-ended December 31, 2013, Avanir estimates: -- Total gross...

2014-01-10 16:22:13

ALISO VIEJO, Calif., Jan. 10, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir announced that on January 7, 2014, the Company approved the grant of stock options to new employees to purchase a total of 249,800 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4). (Logo:...